Growth Potential Assets


Revenue Generative Assets

Altan is a specialty pharmaceutical company that develops, manufactures and markets injectable medications for the hospital and other provider segments. Altan is a premier, global injectable drug company that is committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers. In June 2021, Altan entered into a definitive agreement with Ethypharm, pursuant to which Ethypharm will acquire all outstanding shares of Altan. The closing of this transaction, which is subject to competition authority filings, is expected during the second half of 2021.

> go to website

Xenex is a commercial-stage UV-light disinfection technology company harnessing the power of xenon light to eliminate pathogens and assist infection control programmes in hospital and other settings. Xenex is the only UV disinfection solution proven effective by more than 40 published, peer-reviewed studies. Xenex solutions are ideally suited for disinfecting hospitality, transportation and other environments to deactivate bacteria, spores and viruses, including SARS-CoV-2, the virus that causes COVID-19.

> go to website

Early-stage Assets

Artizan is an early-stage biotechnology company focused on leveraging its proprietary IgA-SEQTM technology platform to identify disease-causing bacteria in the gut microbiota, with the goal of developing new and potentially curative treatments. This approach is applicable to a variety of microbiota-driven diseases including inflammatory bowel disease (IBD), central nervous system disorders, obesity, metabolic syndrome and autoimmune disease.

> go to website

Wren is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden) focused on drug discovery and development for protein misfolding diseases including Alzheimer's and Parkinson's. Wren’s proprietary approach is based on more than a decade of research focused on the chemical kinetics of the protein misfolding process. Wren is advancing a broad pipeline of small molecule therapeutic candidates, as well as antibody diagnostics, for a number of high-value targets, including alpha-synuclein, amyloid-beta, IAPP, tau and TDP-43.

> go to website